The seven gold medals in swimming invest… They have reported eight gold medals, the 21 won by France in the European Championships in Budapest. Just back in France, the French hero on Monday night were the guests of Harry Roselmack, who took the opportunity to ask the return of Laure Manaudou compagnon.Ces its non-believers who are the people ramadanCertaines Ramadan without have no religious belief. Not always in solidarity to their colleagues or companions musulmans.Dans the bowels of the earth with the rescue… They are the ones who dig our basement, exploring it and protect it. During 24 hours, a team of rescuers TF1 accompanies cavers during a rescue exercise at 200 m underground in Lozere…

Another pharmaceutical company wishing to afford a biotech company. This time, it is the American Bristol-Myers Squibb (BMS). Advised by Morgan Stanley, Citigroup and Credit Suisse, it has launched yesterday an offer unsolicited $ 60 per share in cash on the 83.4% stake in compatriot ImClone it does not hold still. The transaction is valued at 4.5 billion dollars (2.9 billion euros). The group, which has 4 billion cash and discusses the transfer of funds to its Convatec division for 4.1 billion, has not detailed the financing of the transaction.

The interest of ImClone in one word: Erbitux. This treatment against colon cancer developed by the biotechnology company has been increasingly successful and might be applied to other forms of the disease, like lung cancer. In the second quarter of 2008, worldwide sales totaled $ 423 million, up 33% over one year. BMS, ImClone, which had joined in 2001 to develop the product, believes it is time to monitor the treatment to 100%.



.